Group 1 - The company Wantaibio announced that its sixth board meeting was held on January 13, 2026, via communication methods, where it reviewed the proposal to amend the "Internal Audit System" [1] Group 2 - The solar industry is experiencing a rush to export products before the April 1 deadline, with some companies facing challenges due to skyrocketing raw material costs, such as silver, leading to difficult decision-making [1]

国金证券股份有限公司 现金管理金额：拟使用最高额度不超过人民币 12 亿元（含），可由公司及 全资子公司共同循环滚动使用。 （三）资金来源 关于北京万泰生物药业股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 国金证券股份有限公司（以下简称"国金证券"、"保荐机构"）作为北京 万泰生物药业股份有限公司（以下简称"万泰生物"、"公司"）的非公开发行 股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金 监管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》等有关规定的要求，对公司使用募集资金进行现金 管理进行了审慎核查，具体情况如下： 一、投资情况概述 （一）投资目的 鉴于公司募投项目均有一定的实施周期，为提高募集资金的使用效率和资金 效益，公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，根据 《上市公司募集资金监管规则》《上海证券交易所上市公司自律监管指引第 1 号 ——规范运作》以及公司《募集资金管理制度》等规定，使用部分闲置募集资金 投资保本型理财产品，有利于提高募集资金的使用效率，增加公司收益，保证股 东利益最大化。 ...

信息披露暂缓与豁免管理制度 二〇二六年一月 北京万泰生物药业股份有限公司 信息披露暂缓与豁免管理制度 北京万泰生物药业股份有限公司 信息披露暂缓与豁免管理制度 北京万泰生物药业股份有限公司 信息披露暂缓与豁免管理制度 北京万泰生物药业股份有限公司 1 第一章 总 则 第一条 为规范北京万泰生物药业股份有限公司（以下简称"公司"）的信 息披露暂缓与豁免行为，保证公司及相关信息披露义务人依法合规履行信息披露 义务，根据《中华人民共和国证券法》《上市公司信息披露管理办法》《上市公 司信息披露暂缓与豁免管理规定》《上海证券交易所股票上市规则》（以下简称 "《上市规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》以及《北京万泰生物药业股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，制定本制度。 第二条 公司按照《上市规则》及交易所其他相关业务规则的规定，办理信 息披露暂缓、豁免业务的，适用本制度。 第三条 公司拟披露的信息存在《上市规则》及交易所其他相关业务规则中 规定的可暂缓、豁免披露情形的，由公司自行审慎判断，并接受上海证券交易所 对有关信息披露暂缓、豁免事项的事后监管。 第二章 ...

北京万泰生物药业股份有限公司 内部审计制度 北京万泰生物药业股份有限公司 内部审计制度 （2026 年 1 月修订） 第一章 总则 第一条 为加强北京万泰生物药业股份有限公司（以下简称"公司"）的 内部审计监督，切实保证公司财务会计制度等各项制度的有效执行和公司资金的 安全有效使用，保护投资者的合法权益，根据《中华人民共和国审计法》《企业 内部控制基本规范》等法律、法规，结合公司实际情况，制定本制度。 北京万泰生物药业股份有限公司 内部审计制度 二〇二六年一月 北京万泰生物药业股份有限公司 内部审计制度 北京万泰生物药业股份有限公司 内部审计制度 第八条 内审部门履行职责所必需工作经费，依照公司管理规定列入公司 年度财务预算予以保障。 第二章 内部审计机构和审计人员 第二条 本制度适用于公司及其所属分公司、全资子公司（含全资子公司 及其之间组建的全资公司）和控股（非全资）子公司（以下简称"各下属单位"）。 第三条 公司的参股单位可参照本制度实施内部审计。 第四条 内部审计是公司经济监督工作的重要组成部分，是内审部门依法 独立监督和评价各下属单位财务收支、经济活动的真实、合法和效益，以及为加 强内部控制和风险管 ...

北京万泰生物药业股份有限公司 内幕信息知情人登记制度 北京万泰生物药业股份有限公司 内幕信息知情人登记制度 二〇二六年一月 北京万泰生物药业股份有限公司 内幕信息知情人登记制度 北京万泰生物药业股份有限公司 内幕信息知情人登记制度 （2026 年 1 月修订） 第一章 总则 第一条 为规范北京万泰生物药业股份有限公司（以下简称"公司"）内幕 信息管理行为，加强公司内幕信息保密工作，维护信息披露的公平原则，根据《中 华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司信息披露管理办法》《上海证券交易所股票上市规则》《上市公司监 管指引第5号——上市公司内幕信息知情人登记管理制度》等有关法律、法规的 规定及《公司章程》《信息披露管理制度》，结合公司实际情况，制定本制度。 第二条 本制度的适用范围为：公司、分公司、子公司（包括公司直接或间 接控股50%以上的子公司和其他纳入公司合并会计报表的子公司）。 第三条 公司内幕信息登记备案工作由公司董事会负责，董事长为主要责任 人。董事会应当保证内幕信息知情人档案真实、准确和完整。董事会秘书负责办 理公司内幕信息知情人的登记入档和报送事宜，当 ...

北京万泰生物药业股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行的审议程序：公司于 2026 年 1 月 13 日召开第六届董事会第十四 次会议，审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，该议 案无需提交股东会审议。 特别风险提示：公司购买标的为保本型的理财产品或存款类产品（包括 但不限于结构性存款、大额存单、通知存款等）属于低风险投资品种，总体风险 可控；但基于金融市场受宏观经济等因素影响，不排除该项投资受到市场波动的 影响，存在一定的系统性风险。 北京万泰生物药业股份有限公司（以下简称"公司"）于2026年1月13日召 开第六届董事会第十四次会议，审议通过了《关于使用部分闲置募集资金进行现 金管理的议案》，同意公司使用最高额度不超过人民币12亿元（含）的暂时闲置 非公开发行股票募集资金适时投资安全性高、流动性好的保本型产品，单项产品 期限最长不超过12个月。该额度自公司董事会审议通过之日起12个月内有效，可 由公司及全资子公司共 ...

北京万泰生物药业股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 证券代码：603392 证券简称：万泰生物 公告编号：2026-002 （一）投资目的 为提高资金使用效率、增加公司收益，在保证公司正常经营所需流动资金和 有效控制风险的前提下，公司拟使用部分闲置自有资金进行现金管理，为公司和 股东谋取较好的投资回报，实现股东利益最大化。 （二）投资金额及资金来源 最高额度不超过人民币45亿元（含）的闲置自有资金，可由公司及全资子公 司、控股子公司共同循环滚动使用。 | 投资金额 | 拟使用最高额度不超过人民币 45 亿元（含），可由公司 | | --- | --- | | | 及全资子公司、控股子公司共同循环滚动使用。 | | 投资种类 | 安全性高、流动性好的低风险投资产品 | | 资金来源 | 自有资金 | 已履行的审议程序：公司于 2026 年 1 月 13 日召开第六届董事会第十四 次会议，审议通过了《关于使用部分闲置自有资金进行现金管理 ...

证券代码：603392 证券简称：万泰生物 公告编号：2026-001 北京万泰生物药业股份有限公司 第六届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2026年1月9日以电 子邮件方式向全体董事发出第六届董事会第十四次会议召开通知和会议材料。本 次会议于2026年1月13日以通讯方式召开。本次会议由公司董事长邱子欣先生主 持，应出席董事9人，实际出席董事9人。本次会议的出席人数、召开和表决方式 符合《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于使用部分闲置自有资金进行现金管理的议案》 表决结果：同意9票、反对0票、弃权0票。 同意公司在保证正常经营、资金安全的前提下，使用最高额度不超过人民币 45亿元（含）的闲置自有资金适时购买安全性高、流动性好的低风险投资产品。 该额度自公司董事会审议通过之日起12个月内有效，可由公司及全资子公司、控 股子公司共同循环滚动使用。 ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Core Viewpoint - Wante Bio's stock price has shown a slight increase of 2.00% recently, but the company has experienced a significant decline in revenue and profit year-on-year, indicating potential challenges ahead [1][2]. Group 1: Stock Performance - As of January 5, Wante Bio's stock price reached 45.84 CNY per share, with a market capitalization of 57.96 billion CNY [1]. - The stock has seen a 2.00% increase year-to-date, but has declined by 2.11% over the last five trading days, 1.46% over the last twenty days, and 21.12% over the last sixty days [1]. Group 2: Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion CNY, a decrease of 23.09% year-on-year [2]. - The company recorded a net profit of -173 million CNY, representing a significant decline of 165.04% compared to the previous year [2]. Group 3: Shareholder Information - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.60% to 30,124 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 9.8553 million shares, and new shareholder招商国证生物医药指数A, holding 4.9609 million shares [3].